|
|||||
|
|
A prospective validation study of sentinel lymph node biopsy in multicentric breast cancer: SMMaC trial |
|
| Authors: | R.F.D. van la Parra W.K. de Roos C.M.E. Contant C.D.L. Bavelaar-Croon P.C. Barneveld K. Bosscha |
| Affiliation: | 1. Department of Surgery, Netherlands Cancer Institute – Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The Netherlands;2. Department of Surgery, Gelderse Vallei Hospital, Ede, The Netherlands;3. Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands;4. Department of Nuclear Medicine, Gelderse Vallei Hospital, Ede, The Netherlands;5. Department of Nuclear Medicine, Jeroen Bosch Hospital, ''s-Hertogenbosch, The Netherlands;6. Department of Surgery, Jeroen Bosch Hospital, ''s-Hertogenbosch, The Netherlands |
| Abstract: | BackgroundMulticentric breast cancer is often considered a contra-indication for sentinel lymph node (SLN) biopsy due to concerns with sensitivity and false negative rate. To assess SLN feasibility and accuracy in multicentric breast cancer, the multi-institutional SMMaC trial was conducted.MethodsIn this study 30 patients with multicentric breast cancer and a clinically negative axilla were prospectively included. Periareolar injection of radioisotope and blue dye was administered. In all patients SLN biopsy was validated by back-up completion axillary lymph node dissection.Resultsthe SLN was successfully identified in 30 of 30 patients (identification rate 100%). The incidence of axillary metastases was 66.7% (20/30). The false negative rate was 0% (0/20) and the sensitivity was 100% (20/20). The negative predictive value was 100% (10/10).ConclusionSLN biopsy in multicentric breast cancer seems feasible and accurate and should therefore be considered in patients with multicentric breast cancer and clinically negative axilla. |
| Keywords: | Sentinel lymph node biopsy Multicentric breast cancer False negative rate Axillary lymph node dissection |
| 本文献已被 ScienceDirect 等数据库收录！ | |